Seres Therapeutics Inc
NASDAQ:MCRB
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.5599
1.56
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MCRB stock under the Base Case scenario is 0.8507 USD. Compared to the current market price of 0.6032 USD, Seres Therapeutics Inc is Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Seres Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MCRB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Seres Therapeutics Inc
Balance Sheet Decomposition
Seres Therapeutics Inc
Current Assets | 149.3m |
Cash & Short-Term Investments | 71.2m |
Receivables | 18.6m |
Other Current Assets | 59.4m |
Non-Current Assets | 172.5m |
PP&E | 121.1m |
Other Non-Current Assets | 51.4m |
Current Liabilities | 108.3m |
Accounts Payable | 4.8m |
Accrued Liabilities | 16.6m |
Other Current Liabilities | 86.8m |
Non-Current Liabilities | 300.5m |
Long-Term Debt | 102.5m |
Other Non-Current Liabilities | 198m |
Earnings Waterfall
Seres Therapeutics Inc
Revenue
|
364k
USD
|
Operating Expenses
|
-155m
USD
|
Operating Income
|
-154.6m
USD
|
Other Expenses
|
-7.6m
USD
|
Net Income
|
-162.2m
USD
|
Free Cash Flow Analysis
Seres Therapeutics Inc
USD | |
Free Cash Flow | USD |
MCRB Profitability Score
Profitability Due Diligence
Seres Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Seres Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
MCRB Solvency Score
Solvency Due Diligence
Seres Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Seres Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MCRB Price Targets Summary
Seres Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for MCRB is 3.9719 USD with a low forecast of 1.01 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for MCRB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 333 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The firm's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). The company is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).
Contact
IPO
Employees
Officers
The intrinsic value of one MCRB stock under the Base Case scenario is 0.8507 USD.
Compared to the current market price of 0.6032 USD, Seres Therapeutics Inc is Undervalued by 29%.